Subcutaneous Administration of Interleukin-2 in Human Immunodeficiency Virus Type 1-Infected Persons (original) (raw)

Journal Article

,

National Institute of Allergy and Infectious Diseases, Critical Care Medicine Department and Pharmacy Department, Warren G. Magnuson Clinical Center, National Institutes of Health

,

Bethesda, Maryland

;

Chiron Corporation

,

Emeryville, California

Reprints or correspondence: Dr. Richard T. Davey, Jr., National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg. 10, Room 11C103, Bethesda, MD 20892-1880.

Search for other works by this author on:

,

National Institute of Allergy and Infectious Diseases, Critical Care Medicine Department and Pharmacy Department, Warren G. Magnuson Clinical Center, National Institutes of Health

,

Bethesda, Maryland

;

Chiron Corporation

,

Emeryville, California

Search for other works by this author on:

,

National Institute of Allergy and Infectious Diseases, Critical Care Medicine Department and Pharmacy Department, Warren G. Magnuson Clinical Center, National Institutes of Health

,

Bethesda, Maryland

;

Chiron Corporation

,

Emeryville, California

Search for other works by this author on:

,

National Institute of Allergy and Infectious Diseases, Critical Care Medicine Department and Pharmacy Department, Warren G. Magnuson Clinical Center, National Institutes of Health

,

Bethesda, Maryland

;

Chiron Corporation

,

Emeryville, California

Search for other works by this author on:

,

National Institute of Allergy and Infectious Diseases, Critical Care Medicine Department and Pharmacy Department, Warren G. Magnuson Clinical Center, National Institutes of Health

,

Bethesda, Maryland

;

Chiron Corporation

,

Emeryville, California

Search for other works by this author on:

,

National Institute of Allergy and Infectious Diseases, Critical Care Medicine Department and Pharmacy Department, Warren G. Magnuson Clinical Center, National Institutes of Health

,

Bethesda, Maryland

;

Chiron Corporation

,

Emeryville, California

Search for other works by this author on:

,

National Institute of Allergy and Infectious Diseases, Critical Care Medicine Department and Pharmacy Department, Warren G. Magnuson Clinical Center, National Institutes of Health

,

Bethesda, Maryland

;

Chiron Corporation

,

Emeryville, California

Search for other works by this author on:

,

National Institute of Allergy and Infectious Diseases, Critical Care Medicine Department and Pharmacy Department, Warren G. Magnuson Clinical Center, National Institutes of Health

,

Bethesda, Maryland

;

Chiron Corporation

,

Emeryville, California

Search for other works by this author on:

,

National Institute of Allergy and Infectious Diseases, Critical Care Medicine Department and Pharmacy Department, Warren G. Magnuson Clinical Center, National Institutes of Health

,

Bethesda, Maryland

;

Chiron Corporation

,

Emeryville, California

Search for other works by this author on:

,

National Institute of Allergy and Infectious Diseases, Critical Care Medicine Department and Pharmacy Department, Warren G. Magnuson Clinical Center, National Institutes of Health

,

Bethesda, Maryland

;

Chiron Corporation

,

Emeryville, California

Search for other works by this author on:

... Show more

Revision received:

14 October 1996

• • Article contents
  • Figures & tables
  • Video
  • Audio
  • Supplementary Data
• Cite

Cite

Richard T. Davey, Doreen G. Chaitt, Stephen C. Piscitelli, Mary Wells, Joseph A. Kovacs, Robert E. Walker, Judith Falloon, Michael A. Polis, Julia A. Metcalf, Henry Masur, Gwendolyn Fyfe, H. Clifford Lane, Subcutaneous Administration of Interleukin-2 in Human Immunodeficiency Virus Type 1-Infected Persons, The Journal of Infectious Diseases, Volume 175, Issue 4, April 1997, Pages 781–789, https://doi.org/10.1086/513971
Close

Navbar Search Filter Mobile Enter search term Search

Abstract

The safety and efficacy were assessed of 5-day cycles of subcutaneous (sc) interleukin-2 (IL-2) every 8 weeks in human immunodeficiency virus type 1-infected outpatients with > 200 CD4 cells/ mm3. Immunologic, virologic, and toxicity parameters were measured in 18 patients receiving standard antiretrovirals plus 5-day courses of sc IL-2 (3–18 MIU/day) every 2 months. Systemic toxicities established the maximally tolerated dose (MTD) of IL-2 as 15 MIU/day. CD4 cell responses appeared to correlate directly with baseline CD4 cell counts, with several patients experiencing a dramatic rise after 3 cycles. Virus load increased only transiently in the peri-injection period. It was concluded that serial cycles of outpatient sc IL-2 can be administered safely, with an MTD of 15 MIU/day. Patients with higher baseline counts appear to have a greater CD4 cell response to sc IL-2 therapy.

This content is only available as a PDF.

© 1997 by The University of Chicago

Topic:

• hiv
• aldesleukin
• cd4 count determination procedure
• cd4 positive t-lymphocytes
• subcutaneous injections
• maximum tolerated dose
• outpatients
• safety
• viral load result
• toxic effect
• anti-retroviral agents
• immunology

You do not currently have access to this article.

Personal account

• Sign in with email/username & password
• Get email alerts
• Save searches
• Purchase content
• Activate your purchase/trial code
• Add your ORCID iD

Get help with access

Institutional access

Access to content on Oxford Academic is often provided through institutional subscriptions and purchases. If you are a member of an institution with an active account, you may be able to access content in one of the following ways:

IP based access

Typically, access is provided across an institutional network to a range of IP addresses. This authentication occurs automatically, and it is not possible to sign out of an IP authenticated account.

Sign in through your institution

Choose this option to get remote access when outside your institution. Shibboleth/Open Athens technology is used to provide single sign-on between your institution’s website and Oxford Academic.

1. Click Sign in through your institution.
2. Select your institution from the list provided, which will take you to your institution's website to sign in.
3. When on the institution site, please use the credentials provided by your institution. Do not use an Oxford Academic personal account.
4. Following successful sign in, you will be returned to Oxford Academic.

If your institution is not listed or you cannot sign in to your institution’s website, please contact your librarian or administrator.

Sign in with a library card

Enter your library card number to sign in. If you cannot sign in, please contact your librarian.

Society Members

Society member access to a journal is achieved in one of the following ways:

Sign in through society site

Many societies offer single sign-on between the society website and Oxford Academic. If you see ‘Sign in through society site’ in the sign in pane within a journal:

1. Click Sign in through society site.
2. When on the society site, please use the credentials provided by that society. Do not use an Oxford Academic personal account.
3. Following successful sign in, you will be returned to Oxford Academic.

If you do not have a society account or have forgotten your username or password, please contact your society.

Sign in using a personal account

Some societies use Oxford Academic personal accounts to provide access to their members. See below.

Personal account

A personal account can be used to get email alerts, save searches, purchase content, and activate subscriptions.

Some societies use Oxford Academic personal accounts to provide access to their members.

Viewing your signed in accounts

Click the account icon in the top right to:

• View your signed in personal account and access account management features.
• View the institutional accounts that are providing access.

Signed in but can't access content

Oxford Academic is home to a wide variety of products. The institutional subscription may not cover the content that you are trying to access. If you believe you should have access to that content, please contact your librarian.

Institutional account management

For librarians and administrators, your personal account also provides access to institutional account management. Here you will find options to view and activate subscriptions, manage institutional settings and access options, access usage statistics, and more.

Purchase

Short-term Access

To purchase short-term access, please sign in to your personal account above.

Don't already have a personal account? Register

Subcutaneous Administration of Interleukin-2 in Human Immunodeficiency Virus Type 1-Infected Persons - 24 Hours access

EUR €38.00

GBP £33.00

USD $41.00

Rental

This article is also available for rental through DeepDyve.

Citations

Views

Altmetric

Metrics

Total Views 690

117 Pageviews

573 PDF Downloads

Since 11/1/2016

×

Email alerts

More on this topic

Related articles in PubMed

Citing articles via

• Latest

• Most Read

• Most Cited

More from Oxford Academic